ApostoliaMaria(Tsimperidou)TsimberidouMDPhD

Hematologic Oncology

Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,

Join to view full profile

Dr. Tsimberidou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tsimberidou's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Aristotle University of Thessaloniki School of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2010 - 2026
OK State Medical License 2020 - 2021

Clinical Trials

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis Start of enrollment: 2007 Jun 01
Completed
Phase 1
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin Start of enrollment: 2006 Jun 01
Completed
Phase 1
Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement Start of enrollment: 2005 Mar 01
Completed
Phase 1
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement Start of enrollment: 2005 Oct 01
Completed
Phase 1
Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol Start of enrollment: 2009 Feb 01
Recruiting
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab Start of enrollment: 2009 Jul 01
Completed
Phase 1
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders Start of enrollment: 2013 May 01
Withdrawn
Phase 1
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Start of enrollment: 2009 Sep 01
Completed
Phase 1
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy Start of enrollment: 2009 Dec 01
Completed
Phase 1
HAI Abraxane With Gemcitabine and Bevacizumab Start of enrollment: 2010 Jan 01
Completed
Phase 1
Bendamustine and Bevacizumab for Advanced Cancers Start of enrollment: 2010 Jun 01
Completed
Phase 1
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) Start of enrollment: 2010 Aug 01
Completed
Phase 1
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Start of enrollment: 2010 Sep 30
Completed
Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies Start of enrollment: 2013 Dec 13
Completed
Phase 1
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II) Start of enrollment: 2014 May 13
Active, not recruiting
Not Applicable
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy Start of enrollment: 2014 Aug 01
Withdrawn
Phase 1
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. Start of enrollment: 2018 May 07
Terminated
Phase 1, Phase 2
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors Start of enrollment: 2018 Jun 07
Terminated
Phase 1, Phase 2
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors Start of enrollment: 2019 Dec 10
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Apostolia Maria Tsimberidou, Axel Grothey, Darren Sigal, Heinz-Josef Lenz, Howard S Hochster
Cancer Chemotherapy and Pharmacology. 2024-12-01
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, Alexandra Drakaki, Danny N Khalil
The Journal of Experimental Medicine. 2024-10-07
8 citations
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01

Journal Articles

A Nonparametric Bayesian Basket Trial Design
Apostolia (Tsimperidou) Tsimberidou, MD, Biometrical Journal

Lectures

Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refr...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period at The IMPACT study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Issue HighlightsAugust 24th, 2020
Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid CancersMarch 19th, 2019
Nature Publication Reports First-in-Human Trial for a Personalized Cancer ImmunotherapyDecember 20th, 2018
Join now to see all